Patents Assigned to MethylGene Inc.
  • Selected inhibitors of protein tyrosine kinase activity
    Patent number: 8455484
    Abstract: The invention provides new compounds and compositions thereof. The invention also provides methods for treating ophthalmic diseases, disorders and conditions.
    Type: Grant
    Filed: April 8, 2011
    Date of Patent: June 4, 2013
    Assignee: MethylGene Inc.
    Inventors: Stéphane Raeppel, Lijie Zhan, Stephen William Claridge, Franck Raeppel, Frédéric Gaudette, Arkadii Vaisburg
  • Inhibitors of beta-lactamase
    Patent number: 8440643
    Abstract: This invention provides novel ?-lactamase inhibitors of the aryl- and heteroaryl-sulfonamidomethylphosphonate monoester class having nitrogen-based cations or quarternary ammomium groups. The compounds inhibit three classes of ?-lactamases and synergize the antibacterial effects of ?-lactam antibiotics (e.g., imipenem and ceftazimdime) against those micro-organisms normally resistant to the ?-lactam antibiotics as a result of the presence of the ?-lactamases.
    Type: Grant
    Filed: May 21, 2007
    Date of Patent: May 14, 2013
    Assignee: MethylGene Inc.
    Inventors: Frank Dininno, Milton L. Hammond, Kevin Dykstra, Seongkon Kim, Qiang Tan, Katherine Young, Jeffrey Donald Hermes, Helen Chen, Stephane Raeppel, Michael Mannion, Frederic Gaudette, Arkadii Vaisburg, Jubrail Rahil, Nafsika Georgopapadakou, Nancy Z. Zhou
  • Selected Inhibitors of Protein Tyrosine Kinase Activity
    Publication number: 20130096135
    Abstract: The present invention provides new compounds and methods for treating a disease responsive to inhibition of kinase activity, for example a disease responsive to inhibition of protein tyrosine kinase activity, for example a disease responsive to inhibition of protein tyrosine kinase activity of growth factor receptors, for example a disease responsive to inhibition of receptor type tyrosine kinase signaling, or for example, a disease responsive to inhibition of VEGF receptor signaling.
    Type: Application
    Filed: September 27, 2012
    Publication date: April 18, 2013
    Applicant: METHYLGENE INC.
    Inventor: MethylGene Inc.
  • Inhibitors of Protein Tyrosine Kinase Activity
    Publication number: 20130096136
    Abstract: The present invention provides new compounds and methods for treating a disease responsive to inhibition of kinase activity, for example a disease responsive to inhibition of protein tyrosine kinase activity, for example a disease responsive to inhibition of protein tyrosine kinase activity of growth factor receptors, for example a disease responsive to inhibition of receptor type tyrosine kinase signaling, or for example, a disease responsive to inhibition of VEGF receptor signaling.
    Type: Application
    Filed: September 27, 2012
    Publication date: April 18, 2013
    Applicant: METHYLGENE INC.
    Inventor: METHYLGENE INC.
  • Inhibitors of Protein Tyrosine Kinase Activity
    Publication number: 20130096088
    Abstract: The present invention provides new compounds and methods for treating a disease responsive to inhibition of kinase activity, for example a disease responsive to inhibition of protein tyrosine kinase activity, for example a disease responsive to inhibition of protein tyrosine kinase activity of growth factor receptors, for example a disease responsive to inhibition of receptor type tyrosine kinase signaling, or for example, a disease responsive to inhibition of VEGF receptor signaling.
    Type: Application
    Filed: September 27, 2012
    Publication date: April 18, 2013
    Applicant: METHYLGENE INC.
    Inventor: METHYLGENE INC.
  • Inhibitors of Protein Tyrosine Kinase Activity
    Publication number: 20130090327
    Abstract: The present invention provides new compounds and methods for treating a disease responsive to inhibition of kinase activity, for example a disease responsive to inhibition of protein tyrosine kinase activity, for example a disease responsive to inhibition of protein tyrosine kinase activity of growth factor receptors, for example a disease responsive to inhibition of receptor type tyrosine kinase signaling, or for example, a disease responsive to inhibition of VEGF receptor signaling.
    Type: Application
    Filed: September 27, 2012
    Publication date: April 11, 2013
    Applicant: METHYLGENE INC.
    Inventor: METHYLGENE INC.
  • Inhibitors of protein tyrosine kinase activity
    Patent number: 8404846
    Abstract: This invention relates to compounds that inhibit protein tyrosine kinase activity. In particular the invention relates to compounds that inhibit the protein tyrosine kinase activity of growth factor receptors, resulting in the inhibition of receptor signaling, for example, the inhibition of VEGF receptor signaling and HGF receptor signaling. More particularly, the invention relates to compounds, compositions and methods for the inhibition of VEGF receptor signaling and HGF receptor signaling. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.
    Type: Grant
    Filed: August 29, 2008
    Date of Patent: March 26, 2013
    Assignee: MethylGene Inc.
    Inventors: Stephen William Claridge, Ljubomir Isakovic, Michael Mannion, Stéphane Raeppel, Oscar Mario Saavedra, Frédéric Gaudette, Lijie Zhan, Arkadii Vaisburg
  • Dibenzo[b,f][1,4]oxazepin-11-yl-N-hydroxybenzamides as HDAC inhibitors
    Patent number: 8399452
    Abstract: This invention relates to compounds for the inhibition of histone deacetylase. More particularly, the invention provides for compounds of formula (I) wherein Q, J, L and Z are as defined in the specification.
    Type: Grant
    Filed: October 26, 2007
    Date of Patent: March 19, 2013
    Assignees: Methylgene Inc., EnVivo Pharmaceuticals
    Inventors: Robert Déziel, Silvana Leit, Patrick Beaulieu, Yves Andre Chantigny, John Mancuso, Pierre Tessier, Gideon Shapiro, Richard Chesworth, David Smil
  • Inhibitors of protein tyrosine kinase activity
    Patent number: 8389541
    Abstract: This invention relates to compounds that inhibit protein tyrosine kinase activity. In particular the invention relates to compounds that inhibit the protein tyrosine kinase activity of growth factor receptors, resulting in the inhibition of receptor signaling, for example, the inhibition of VEGF receptor signaling and HGF receptor signaling. More particularly, the invention relates to compounds, compositions and methods for the inhibition of VEGF receptor signaling and HGF receptor signaling. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.
    Type: Grant
    Filed: December 30, 2011
    Date of Patent: March 5, 2013
    Assignee: MethylGene Inc.
    Inventors: Stephen William Claridge, Ljubomir Isakovic, Michael Mannion, Stephane Raeppel, Oscar Mario Saavedra, Frederic Gaudette, Lijie Zhan, Arkadii Vaisburg
  • Inhibitors of histone deacetylase
    Patent number: 8354445
    Abstract: The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions. One aspect of the invention provides compounds of formula (1): in which T, A and X are as described herein.
    Type: Grant
    Filed: May 11, 2011
    Date of Patent: January 15, 2013
    Assignee: MethylGene Inc.
    Inventors: Sylvie Frechette, Lubo Isakovic, Isabelle Paquin, Simon Roy, Oscar Moradei, Arkadii Vaisburg
  • Amines as small molecule inhibitors
    Patent number: 8338437
    Abstract: The present invention relates to compounds that are useful as inhibitors of protein arginine methyltransferase that have a formula selected from Formula (I), Formula (II) and Formula (III), as well as racemic mixtures, diastereomers, enantiomers and tautomers thereof and N-oxides, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof as defined herein. The compound are useful as inhibitors of PRMTs and/or CARM-I. The invention further relates to compositions comprising such compounds and methods for their use.
    Type: Grant
    Filed: February 28, 2008
    Date of Patent: December 25, 2012
    Assignee: MethylGene Inc.
    Inventors: Amal Wahhab, Eric Therrien, Martin Allan, Sukhdev Manku
  • Inhibitors of VEGF receptor and HGF receptor signaling
    Patent number: 8329726
    Abstract: The invention relates to the inhibition of VEGF receptor signaling and HGF receptor signaling. The invention provides compounds of general formula (A) wherein A1 is sulfur, A3 is CH, A2 is CH, D is heterocycle, Z is oxygen, SO0-2 or NR, Ar is phenyl and G is not a ring, and methods for inhibiting VEGF receptor signaling and HGF receptor signaling. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.
    Type: Grant
    Filed: December 8, 2011
    Date of Patent: December 11, 2012
    Assignee: MethylGene Inc.
    Inventors: Oscar Mario Saavedra, Stephen William Claridge, Lijie Zhan, Franck Raeppel, Arkadii Vaisburg, Stephane Raeppel, Michael Mannion, Frederic Gaudette, Ljubomir Isakovic, Marie-Claude Granger, Naomy Bernstein
  • Fused heterocycles as inhibitors of VEGF receptor and HGF receptor signaling
    Patent number: 8093264
    Abstract: The invention relates to the inhibition of VEGF receptor signaling and HGF receptor signaling. The invention provides compounds of general formula (A) wherein A1 is sulfur, A3 is CH, A2 is CH, D is heterocycle, Z is oxygen, SO0-2 or NR, Ar is phenyl and G is not a ring, and methods for inhibiting VEGF receptor signaling and HGF receptor signaling. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.
    Type: Grant
    Filed: May 19, 2006
    Date of Patent: January 10, 2012
    Assignee: Methylgene Inc.
    Inventors: Oscar Mario Saavedra, Stephen William Claridge, Lijie Zhan, Franck Raeppel, Arkadii Vaisburg, Stephane Raeppel, Michael Mannion, Frederic Gaudette, Ljubomir Isakovic, Marie-Claude Granger, Naomy Bernstein
  • Inhibitors of histone deacetylase
    Patent number: 8088805
    Abstract: The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.
    Type: Grant
    Filed: March 16, 2007
    Date of Patent: January 3, 2012
    Assignee: MethylGene Inc.
    Inventors: Daniel Delorme, Silvana Marcela Leit de Moradei, Sylvie Frechette
  • Inhibitors of histone deacetylase
    Patent number: 8030344
    Abstract: The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions. One aspect of the invention provides compounds of formula (1): in which T, A and X are as described herein.
    Type: Grant
    Filed: March 6, 2008
    Date of Patent: October 4, 2011
    Assignee: MethylGene Inc.
    Inventors: Sylvie Frechette, Lubo Isakovic, Isabelle Paquin, Simon Roy, Oscar Moradei, Arkadii Vaisburg
  • Inhibitors of Histone Deacetylase
    Publication number: 20110212965
    Abstract: The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions. One aspect of the invention provides compounds of formula (1): in which T, A and X are as described herein.
    Type: Application
    Filed: May 11, 2011
    Publication date: September 1, 2011
    Applicant: METHYLGENE INC.
    Inventors: Sylvie Frechette, Lubo Isakovic, Isabelle Paquin, Simon Roy, Oscar Moradei, Arkadii Vaisburg
  • INHIBITORS OF HISTONE DEACETYLASE
    Publication number: 20110021771
    Abstract: This invention relates to compounds and methods for the inhibition of HDAC enzymatic activity. More particularly, the invention provides for compounds of formula (I), (I) and N-oxides, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof, and racemic and scalemic mixtures, diastereomers and enantiomers thereof, wherein L, M, n, R, W, X and Y are as defined in the specification.
    Type: Application
    Filed: November 3, 2008
    Publication date: January 27, 2011
    Applicant: METHYLGENE INC.
    Inventors: Tammy Mallais, Oscar Moradei, Alain Ajamian, Pierre Tessier, David Smil, Sylvie Frechette, Roger Machaalani, Silvana Leit, Patrick Beaulieu, Robert Déziel, John Mancuso
  • Inhibitors of histone deacetylase
    Patent number: 7868204
    Abstract: The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.
    Type: Grant
    Filed: March 25, 2005
    Date of Patent: January 11, 2011
    Assignee: MethylGene Inc.
    Inventors: Daniel Delorme, Soon Hyung Woo, Arkadii Vaisburg, Oscar Moradei, Silvana Leit, Stephane Raeppel, Sylvie Frechette, Giliane Bouchain
  • Inhibitors of histone deacetylase
    Patent number: 7868205
    Abstract: The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.
    Type: Grant
    Filed: September 24, 2004
    Date of Patent: January 11, 2011
    Assignee: MethylGene Inc.
    Inventors: Oscar Moradei, Isabelle Paquin, Silvana Leit, Sylvie Frechette, Arkadii Vaisburg, Jeffrey M. Besterman, Pierre Tessier, Tammy C. Mallais
  • Inhibitors of histone deacetylase
    Patent number: RE43343
    Abstract: The invention relates to the inhibition of histone deactylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.
    Type: Grant
    Filed: September 10, 2009
    Date of Patent: May 1, 2012
    Assignee: Methylgene Inc.
    Inventors: Daniel Delorme, Rejean Ruel, Rico Lavoie, Carl Thibault, Elie Abou-Khalil